Partial
Mostly Aligned
Patient Risk:
Low
Summary
The response accurately summarizes multiple on-label indications, selected efficacy-study outcomes, key safety points, and the diphenylheptane/opioid limitation. However, it provides no specific AI medical claim to map to the label and includes meta-statements indicating an inability to evaluate without the exact claim text, which limits assessment of alignment to the requested claim.
Category Scores
Accurate Statements
Amitiza is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Section 1.1 Indications and Usage.
Amitiza is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Section 1.2 Indications and Usage.
Amitiza is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.
Section 1.3 Indications and Usage.
The effectiveness of Amitiza in OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established.
Section 1.2 Limitations of Use; Section 7.1 Methadone; Section 14.2 subgroup signal.
Amitiza is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Section 4 Contraindications.
Patients may experience nausea; concomitant administration of food may reduce nausea symptoms.
Section 5.1 Nausea.
Avoid use of Amitiza in patients with severe diarrhea; instruct patients to discontinue and contact their healthcare provider if severe diarrhea occurs.
Section 5.2 Diarrhea.
Unsupported Statements
The prompt content focuses on indications and clinical efficacy rather than a specific medical claim such as “reduces nausea” or “does not cause diarrhea.” I therefore extracted the label sections most directly relevant to indications/uses and efficacy evidence, plus core safety/contraindication language that could affect effectiveness or use.
This is a meta-description of the user’s prompt strategy rather than a claim about the drug label; it cannot be verified as a label-supported statement.
However, no specific medical claim was included in the prompt to assess (e.g., no statement such as “reduces nausea,” “does not cause diarrhea,” etc.).
The provided prompt content itself is not a label excerpt; without the exact claim text, this is not verifiable as label support.
Contradictions
Important Omissions
The response lists multiple label-related excerpts but does not provide the exact medical claim(s) the user wants evaluated; therefore it omits the necessary claim-to-label mapping step required for a complete alignment assessment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No unsafe dosing or contraindication-violating instructions were provided. The response primarily summarizes label sections and notes a limitation of efficacy for diphenylheptane opioids.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Alignment assessment cannot be fully performed because no exact medical claim text was provided for claim-by-claim label verification.
Suggested Improvement
Provide the exact medical claim sentence(s) to evaluate so each component can be mapped to specific label language and classified as supported/partially supported/absent/contradicted.